Programmed death receptor 1 (PD-1) or programmed death ligand 1 (PD-L1) antibodies, including pembrolizumab, sintilimab, tislelizumab, and atezolizumab, played essential roles increasingly in the HCC clinical practice. Here, CD274 is linked to hepatocellular carcinoma.